AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35477611 — intervention group
Group type: EXPERIMENTAL
Intervention: REL-1017 25 mg QD
Number of subjects: 56
Study 35477611 — intervention group
Group type: EXPERIMENTAL
Intervention: REL-1017 50 mg QD
Number of subjects: 56
Study 35477611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33400384 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy‐based care program (RTCP)
Number of subjects: 192
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign thyroid diseases (hyperthyroidism)
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of TC
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure of the head
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of thyroid diseases
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of other types of cancer
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education (college vs. illiterate)
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of unsaturated fat (vs. saturated)
Number of subjects: 708
Study 33634859 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married (vs. single)
Number of subjects: 708
Study 32302246 — intervention group
Group type: EXPERIMENTAL
Intervention: SPW exercises with six weekly sessions and home practice
Number of subjects: 37
Study 32302246 — intervention group
Group type: COMPARATOR
Intervention: Vocal hygiene education
Number of subjects: 37
Study 34215784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency cannabis flower with CBD
Number of subjects: 80
Study 34215784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency cannabis flower without CBD
Number of subjects: 80
Study 34215784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency cannabis concentrates with CBD
Number of subjects: 80
Study 34215784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency cannabis flower with CBD, high-potency flower without CBD, and high-potency concentrates
Number of subjects: 80
Study 34215784 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (in high-potency cannabis products)
Number of subjects: 80
Study 34215784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency cannabis concentrates
Number of subjects: 80
Study 35192206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand preparation with medicated solution (4% w/v chlorhexidine bigluconate followed by an ABHR)
Number of subjects: 103
Study 35192206 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of a medication solution (benzalkonium chloride 0.1%‐1% and polymeric biguanide hydrochloride 0.01%‐0.1%) followed by an ABHR
Number of subjects: 103
Study 35192206 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedicated pH‐neutral soap hand wash followed by ABHR
Number of subjects: 103
Study 35192206 — intervention group
Group type: COMPARATOR
Intervention: Direct application of an ABHR
Number of subjects: 103
Study 34307321 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRP (autologous platelet- and extracellular vesicle-rich plasma)
Number of subjects: 22
Study 34307321 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative methods (control group)
Number of subjects: 22
Study 35791755 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q8W
Number of subjects: 530
Study 32248403 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology group (n=50)
Number of subjects: 100
Study 32248403 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 100
Study 36123240 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular analgesia with ropivacaine 300 mg and morphine 5 mg, diluted with saline to 50 ml, plus tranexamic acid (TXA) 2 g injected into the articular cavity after surgery.
Number of subjects: 100
Study 36123240 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular injection of 70 mL mixture (ropivacaine 300 mg, morphine 5 mg, and TXA 2 g) after stitching of the joint capsule.
Number of subjects: 100
Study 32072838 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental self-efficacy in asthma care
Number of subjects: 252
Study 32072838 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in using medications correctly
Number of subjects: 252
Study 32072838 — intervention group
Group type: EXPERIMENTAL
Intervention: Having inhalers during a child's serious breathing problem
Number of subjects: 252
Study 32072838 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowing which medications to use during a child's serious breathing problem
Number of subjects: 252
Study 32072838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic/Latino ethnicity of the child
Number of subjects: 252
Study 32072838 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Test scores
Number of subjects: 252
Study 32530523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 3057
Study 32530523 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 3057
Study 35277404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-participated medication reconciliation
Number of subjects: 0
Study 35277404 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 32029487 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose haemodiafiltration (HDF)
Number of subjects: 1800
Study 32029487 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis (HD)
Number of subjects: 1800
Study 34301679 — intervention group
Group type: EXPERIMENTAL
Intervention: Malay ethnicity
Number of subjects: 915
Study 34301679 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian ethnicity
Number of subjects: 915
Study 34301679 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing type (one to three rooms)
Number of subjects: 915
Study 34301679 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing type (four to five rooms public housing)
Number of subjects: 915
Study 34301679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SES
Number of subjects: 915
Study 32220632 — intervention group
Group type: EXPERIMENTAL
Intervention: SAHELI intervention (group-based lifestyle change program with weekly classes for 16 weeks and 4 booster classes through month 11)
Number of subjects: 550
Study 32220632 — intervention group
Group type: COMPARATOR
Intervention: Printed healthy lifestyle education materials (control group)
Number of subjects: 550
Study 35046509 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (1 mg)
Number of subjects: 83
Study 35046509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 34334102 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury-preventive warmup protocol (PEP)
Number of subjects: 18
Study 34334102 — intervention group
Group type: COMPARATOR
Intervention: Standard warmup protocol
Number of subjects: 18
Study 36255427 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord burst stimulation
Number of subjects: 50
Study 36255427 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 50
Study 34127632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level secretors (LLS)
Number of subjects: 16
Study 35229557 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Transplant (RT) patients
Number of subjects: 90
Study 35229557 — intervention group
Group type: COMPARATOR
Intervention: Dialysis patients
Number of subjects: 90
Study 34096066 — intervention group
Group type: EXPERIMENTAL
Intervention: Points gain condition
Number of subjects: 0
Study 34096066 — intervention group
Group type: EXPERIMENTAL
Intervention: Points loss condition
Number of subjects: 0
Study 34096066 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative-only feedback condition
Number of subjects: 0
Study 33045870 — intervention group
Group type: EXPERIMENTAL
Intervention: J-shaped stylet
Number of subjects: 222
Study 33045870 — intervention group
Group type: COMPARATOR
Intervention: 60° stylet
Number of subjects: 222
Study 35325831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg PQQ.Na2
Number of subjects: 96
Study 35325831 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg PQQ.Na2
Number of subjects: 96
Study 35325831 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg PQQ.Na2
Number of subjects: 96
Study 35325831 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg PQQ.Na2 (Control)
Number of subjects: 96
Study 35917826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose Computed Tomography (LDCT) screening at baseline and after 12 months
Number of subjects: 12100
Study 35917826 — intervention group
Group type: COMPARATOR
Intervention: Control group of low-risk participants
Number of subjects: 12100
Study 33673158 — intervention group
Group type: EXPERIMENTAL
Intervention: OP group (OPTIFAST®)
Number of subjects: 273
Study 33673158 — intervention group
Group type: COMPARATOR
Intervention: FB group (food-based dietary intervention)
Number of subjects: 273
Study 33673158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 273
Study 33847066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA) 4 mg/0.1 cc at the end of surgery
Number of subjects: 80
Study 33847066 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac sodium 0.1% TID for 1 month post-operation
Number of subjects: 80
Study 33847066 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (NAT)
Number of subjects: 80
Study 33594912 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG‐EM guidance
Number of subjects: 120
Study 33594912 — intervention group
Group type: COMPARATOR
Intervention: FX guidance
Number of subjects: 120
Study 36001405 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis and self-care
Number of subjects: 0
Study 36001405 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypnosis
Number of subjects: 0
Study 36001405 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hypnosis intervention
Number of subjects: 0
Study 32069742 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term stay in a mountainous, climate-cooler setting (mean ± SD: 7 ± 3 days)
Number of subjects: 31
Study 34775221 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics group
Number of subjects: 42
Study 34775221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 32709920 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin 0.64 mg a.i./L
Number of subjects: 10
Study 32709920 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin 1.40 mg a.i./L
Number of subjects: 10
Study 32709920 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin 15.03 mg a.i./L
Number of subjects: 10
Study 32709920 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin doses < 3.10 mg a.i./L
Number of subjects: 10
Study 32709920 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin doses > 3.10 mg a.i./L
Number of subjects: 10
Study 32709920 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 10
Study 36432420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 5:2 plus (n = 42)
Number of subjects: 131
Study 36432420 — intervention group
Group type: COMPARATOR
Intervention: Daily calorie restriction (n = 41)
Number of subjects: 131
Study 36432420 — intervention group
Group type: COMPARATOR
Intervention: Daily calorie restriction with meal replacement (n = 48)
Number of subjects: 131
Study 33902400 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask during maximal exercise intensity (N95MAX)
Number of subjects: 144
Study 33902400 — intervention group
Group type: EXPERIMENTAL
Intervention: SURGICAL mask during maximal exercise intensity (SURMAX)
Number of subjects: 144
Study 33902400 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask during submaximal exercise intensity (N95SUB)
Number of subjects: 144
Study 33902400 — intervention group
Group type: EXPERIMENTAL
Intervention: SURGICAL mask during submaximal exercise intensity (SURSUB)
Number of subjects: 144
Study 33902400 — intervention group
Group type: COMPARATOR
Intervention: NO MASK
Number of subjects: 144
Study 33902400 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask for females
Number of subjects: 144
Study 33902400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematological function
Number of subjects: 144
Study 33440370 — intervention group
Group type: COMPARATOR
Intervention: Ascitic fluid IL‐4, IL‐6, and IL‐10 levels in patients with hepatocellular carcinoma (HCC)
Number of subjects: 45
Study 33440370 — intervention group
Group type: COMPARATOR
Intervention: Ascitic fluid TNF‐α and IFN‐γ levels in patients with hepatocellular carcinoma (HCC)
Number of subjects: 45
Study 33440370 — intervention group
Group type: COMPARATOR
Intervention: Ascitic fluid IL‐1B and IL‐2 levels
Number of subjects: 45
Study 33440370 — intervention group
Group type: COMPARATOR
Intervention: Ascitic fluid IL‐2 and IL‐10 levels
Number of subjects: 45
Study 33440370 — intervention group
Group type: COMPARATOR
Intervention: Ascitic fluid levels of IL‐4, IL‐6, and IL‐10
Number of subjects: 45
Study 32172380 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to higher concentration of low-density lipoprotein particles (LDL.P)
Number of subjects: 34217
Study 32172380 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to cholesterol carried in different sizes of LDL.P (LDL.C)
Number of subjects: 34217
Study 32172380 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted LDL.P
Number of subjects: 34217
Study 32172380 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted LDL.C
Number of subjects: 34217
Study 34619108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4304
Study 34619108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 32243363 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing + PDT
Number of subjects: 34
Study 32243363 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing + PDT placebo
Number of subjects: 34
Study 33725859 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised heavy‐load resistance training (RT) twice a week over the course of chemotherapy (approximately 16‐weeks)
Number of subjects: 50
Study 33725859 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control group)
Number of subjects: 50
Study 32012398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education pathway
Number of subjects: 180
Study 32012398 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 34351566 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic group (0.15‐0.2 mL of 1.7% sodium hyaluronate injected into the anterior chamber)
Number of subjects: 30
Study 34351566 — intervention group
Group type: COMPARATOR
Intervention: Air group (anterior chamber filled with air after FCVB implant surgery)
Number of subjects: 30
Study 616121226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept (IAI) single injection (2.0 mg 5 days prior to surgery)
Number of subjects: 12
Study 616121226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept (IAI) double injection (2.0 mg 5 days prior to surgery and additional injection at the time of surgery)
Number of subjects: 12
Study 34010747 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of EVOO-enriched chocolate
Number of subjects: 25
Study 34010747 — intervention group
Group type: COMPARATOR
Intervention: Control chocolate spread
Number of subjects: 25
Study 33353067 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance on an air dissipation platform (ADP)
Number of subjects: 25
Study 33353067 — intervention group
Group type: COMPARATOR
Intervention: Aerobic dance on a hard surface
Number of subjects: 25
Study 35818141 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT-tablet
Number of subjects: 0
Study 35818141 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-grass SLIT-tablet
Number of subjects: 0
Study 35818141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed SLIT-tablet
Number of subjects: 0
Study 35818141 — intervention group
Group type: EXPERIMENTAL
Intervention: House-dust mite SLIT-tablet
Number of subjects: 0
Study 35818141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree SLIT-tablet
Number of subjects: 0
Study 35818141 — intervention group
Group type: COMPARATOR
Intervention: SLIT-tablets
Number of subjects: 0
Study 33792376 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 68
Study 33792376 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 68
Study 33792376 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron and dexamethasone
Number of subjects: 68
Study 32248662 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed interim decision procedure based on conditional power approach
Number of subjects: 0
Study 32248662 — intervention group
Group type: COMPARATOR
Intervention: Standard approaches
Number of subjects: 0
Study 32248662 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed methods in adaptive designs
Number of subjects: 0
Study 35358319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care interventions (PC)
Number of subjects: 206
Study 35358319 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (Control arm)
Number of subjects: 206
Study 34312486 — intervention group
Group type: EXPERIMENTAL
Intervention: DoubledyneTM
Number of subjects: 144
Study 34312486 — intervention group
Group type: EXPERIMENTAL
Intervention: TwinTM
Number of subjects: 144
Study 34666724 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families, Strengthening Communities (SFSC) parenting programme
Number of subjects: 0
Study 34666724 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 33079883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometry monitoring
Number of subjects: 86
Study 33079883 — intervention group
Group type: COMPARATOR
Intervention: SPI monitoring
Number of subjects: 86
Study 35440450 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based coronary calcium score (CCS) test
Number of subjects: 800
Study 35440450 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 800
Study 33166179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 85
Study 33166179 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 85
Study 34610147 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 50
Study 33393084 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 1 ng/kg/min infusion for 72 hours
Number of subjects: 220
Study 33393084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume of saline)
Number of subjects: 220
Study 36323988 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide 5 mg subcutaneously once weekly for 6 weeks
Number of subjects: 45
Study 36323988 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide 10 mg subcutaneously once weekly for 6 weeks
Number of subjects: 45
Study 36323988 — intervention group
Group type: COMPARATOR
Intervention: Glepaglutide 1 mg intravenous infusion
Number of subjects: 45
Study 36323988 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline as a pharmacodynamic biomarker
Number of subjects: 45
Study 33681357 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D preoperative planning and 3D printed guide
Number of subjects: 53
Study 33681357 — intervention group
Group type: COMPARATOR
Intervention: Traditional operation (2D templates)
Number of subjects: 53
Study 32743813 — intervention group
Group type: EXPERIMENTAL
Intervention: D-PLEX
Number of subjects: 81
Study 32743813 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 81
Study 36122493 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (Geriatric Nursing Theory + Seminar with age simulation suit + student-older adult interaction)
Number of subjects: 70
Study 36122493 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed experimental group (Geriatric Nursing Theory + Seminar without Age simulation suit + student-older adult interaction + Age simulation suit)
Number of subjects: 70
Study 36122493 — intervention group
Group type: COMPARATOR
Intervention: Control group (only received theoretical contents of the seminar)
Number of subjects: 70
Study 33235121 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Yiqi Huayu Jiedu decoction
Number of subjects: 298
Study 33235121 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy combined with placebo
Number of subjects: 298
Study 34782701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for 12 weeks plus fluoxetine
Number of subjects: 94
Study 34782701 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) for 12 weeks plus placebo
Number of subjects: 94
Study 32139343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (SA group)
Number of subjects: 0
Study 32139343 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-sufentanil based intravenous anesthesia (IA group)
Number of subjects: 0
Study 36058819 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture Therapy (LAT)
Number of subjects: 106
Study 36058819 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 106
Study 33952731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified crystal salt enriched with iron, iodine, vitamin B12, folic acid, and zinc
Number of subjects: 212
Study 33952731 — intervention group
Group type: COMPARATOR
Intervention: Regular non-fortified salt
Number of subjects: 212
Study 32469318 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information needs classification system
Number of subjects: 1000
Study 36316843 — intervention group
Group type: EXPERIMENTAL
Intervention: KGC deer antler extract
Number of subjects: 100